Bioterrorism
Origen Therapeutics Receives $2 Million ATP Grant to Advance Technology for Discovery and Production of Human Polyclonal Antibodies from Transgenic Chickens
Published in Drug Week, October 19th, 2007
Origen Therapeutics announced that the company has been awarded an Advanced Technology Program (ATP) grant totaling $2 million from the National Institute of Standards and Technology (NIST), a division of the U.S. Department of Commerce. The three year grant will help fund development of a new method for discovering and producing human polyclonal antibodies to treat human disease by inserting complex genetic modifications into the chicken genome, enabling the chickens to deposit large amounts of the therapeutic antibodies into their eggs. Origen's first objective will be to develop polyclonal antibodies to treat antibiotic-resistant infections like Staphylococcus aureus in intensive care...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-10-19)
More Articles from Drug Week
- Addiction Medicine
Scripps research study reveals mechanism behind nicotine dependency - Angiogenesis
Combination therapy reverses effects of portal hypertension in rats - Biomedicine
FDA approves knee-injury device for humans - Breast Cancer
Manchester researchers announce new methods of beating breast cancer - Cancer
MU researchers studying model to learn why certain cancers become resistant to drugs - Cancer
New strategies with greater anti tumorous efficacy - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
